Vertex ( ($VERX) ) has shared an update. On October 30, 2025, Vertex‘s Board of Directors authorized a stock repurchase program for up to $150 ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vertex Pharmaceuticals Inc. is conducting ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein ...

- Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - ...

Vertex Pharmaceuticals (VRTX) announced several important updates across its development program for povetacicept, an investigational recombinant fusion protein therapeutic and dual antagonist of the ...

Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the ...

Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - Second pivotal development ...

A longtime child welfare agency in Dearborn Heights announced it is ending a residential treatment program for young girls. In a statement posted on its website Wednesday, Vista Maria officials said ...